To see how thyroid replacement affects lipid profile,anti TPO-antibody,hs-CRP levels in patients who are newly diagnosed cases of hypothyroidism
Not Applicable
- Conditions
- Health Condition 1: E039- Hypothyroidism, unspecified
- Registration Number
- CTRI/2024/02/063073
- Lead Sponsor
- Rucha Sawant
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Yet Recruiting
- Sex
- Not specified
- Target Recruitment
- 0
Inclusion Criteria
Patients with clinical features suggestive of hypothyroidism and diagnosis made as per report of thyroid profile.
Exclusion Criteria
1. Patients who were not on any thyroid supplement.
2. Patients on antithyroid drugs( carbimazole, methimazole, propylthiouracil)
3. DM (Diabetes mellitus).
4. CAD (Coronary artery disease).
5. Critically ill patients.
6. CKD( chronic kidney disease)
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method 1.Lipid Profile Improvement: The study will evaluate whether Levothyroxine treatment leads to significant changes in these lipid parameters, potentially demonstrating improvements in cardiovascular risk factors. <br/ ><br>2.Anti-TPO Antibody Levels: This assessment aims to determine whether Levothyroxine replacement therapy has any discernible effect on the autoimmune component of hypothyroidism by monitoring the Anti-TPO Ab levels over the course of the study. <br/ ><br>3.hsCRP Levels: Elevated hsCRP is indicative of increased inflammation and is associated with various cardiovascular risks. The study aims to discern whether Levothyroxine treatment influences hsCRP levels, potentially indicating a reduction in inflammation and related risks. <br/ ><br>Timepoint: the data will be assessed between the time period of 1.5 years,i.e:01/09/2022 to 31/03/2024
- Secondary Outcome Measures
Name Time Method as per the literature review available the correlation with levels of lipid Profile, anti-TPO antibody, and hsCRP with the treatment of newly diagnosed hypoparathyroidism will be positiveTimepoint: 1.5 years